The aim of this study was to detect the expression of fork-head box D3 (FOXD3) and investigate its diagnostic value in patients with non-small cell lung cancer (NSCLC).
Background
Lung cancer, the main cause of cancer-related deaths, is the most common malignancy all over the world [1] . NSCLC is a common disease and accounts for about 80% of all lung cancers [2, 3] . Currently, the main treatments for NSCLC patients are surgical resection, radiation therapy, and chemotherapy [4, 5] . Although remarkable improvements have been made in those treatments, the curative effects are still unsatisfactory and over 160 000 patients die per year worldwide [6, 7] . Because most NSCLC patients are diagnosed at late stage, the prognosis of NSCLC patients is poor and the 5-year survival rate for NSCLC patients is less than 15% [8] [9] [10] . Therefore, novel and available bio-markers for the diagnosis of NSCLC patients are urgently need.
Fork-head box D3 (FOXD3) is a protein-coding gene that locates at chromosome 1p 31.3 and a winged-helix transcription factor that belongs to the fork-head box (FOX) transcription factor family [11] [12] [13] . It was initially identified because of its expression in embryonic stem cells, and it plays multiple important roles in vertebrate embryogenesis, including control of dorsal mesoderm formation, maintenance of self-renewal and multipotency of stem cells, and regulation of neural crest development [14] [15] [16] [17] [18] . Ectopic expression of FOXD3 has been proved to suppress the invasion, migration, and spheroid outgrowth of mutant B-RAF melanoma cells [19] . In addition, dysregulation of FOXD3 has been observed in gastric cancer, breast cancer, and neuroblastoma [20] [21] [22] . However, its diagnostic value in NSCLC has rarely been reported.
In the present study, we investigated the expression of FOXD3 and analyzed the correlation of FOXD3 expression and clinical features. We also assessed the diagnostic role of FOXD3 in NSCLC.
Material and Methods

Patients
The present study was performed in the Fourth Affiliated Hospital of China Medical University and was approved by the Ethics Committee of the Fourth Affiliated Hospital of China Medical University during April 2011 and June 2015. A total of 131 patients who were diagnosed with NSCLC were enrolled in the present study. None of the patients had received any preoperative treatment, including radiotherapy and chemotherapy, before sampling. In addition, 63 healthy volunteers were enrolled as healthy controls. Written informed consent was provided by each participant in advance.
We obtained 10 ml peripheral blood from each participant and stored the samples at room temperature. After centrifugation at 3000 rpm at 4°C, the obtained serum was put into EDTA blood collection tubes and stored at -80°C until use. Clinicopathologic characteristics of each patient were recorded in a database.
RNA extraction and qRT-PCR analysis
Total RNA was extracted from serum samples using the mirVana miRNA Isolation Kit (Ambion, Austin, TX, USA). Then, the first chain of cDNA was synthesized via reverse transcription using the Primer Script RT Master Kit (TAKARA, China). RT-PCR reaction was performed using the Applied Biosystems 7900 Fast Real-Time PCR system (Applied Biosystems, USA). U6 small nuclear (U6) was used as internal control. The relative mRNA expression of FOXD3 was calculated using the 2 -DDt method. Each sample was assessed in triplicate.
Western blotting
Total protein was isolated from all samples. The protein concentration was determined using the BCA Protein Assay Kit (Pierce, Rockford, IL, USA) and separated by 10% sodium dodecyl sulfate-polyacrylamide gel for electrophoresis (SDS-PAGE). The brands were transferred onto nitrocellulose filter membranes. After the membranes were blocked with 5% nonfat milk, they were incubated with primary antibodies against FOXD3 or GPADH (Abcam, Cambridge, MA, USA), followed by incubation with horseradish peroxidase-conjugated IgGs. Target protein was detected by an enhanced chemiluminescence substrate kit (Pierce Biotechnology, Rockford, IL, USA).
Statistical analysis
The data were analyzed using SPSS 18.0 software and the figures were designed with GraphPad Prism 5. The differences between 2 groups were analyzed by t test. The chi-square test was used to analyze the relationship of FOXD3 expression with clinical parameters of NSCLC patients. The ROC curve was plotted to evaluate the diagnostic value of FOXD3 in patients with NSCLC compared to healthy controls. The difference was considered to be statistically significant when P was less than 0.05.
Results
Down-regulation of serum FOXD3 at mRNA level was observed in NSCLC patients
The relative mRNA expression of serum FOXD3 in NSCLC patients and healthy controls was determined by qRT-PCR analysis. As shown in Figure 1, (Figure 3) , the optimal cutoff point of FOXD3 expression was 2.38. Based on the cutoff point, a sensitivity of 77.1% and a specificity of 74.6% were obtained.
Discussion
NSCLC is a common, slow-developing lung cancer with complex pathogenesis; its progression involves in not only several stages, but also many oncogenes and tumor suppressor genes [23, 24] . Bai et al. found that miR-32 was associated with progression and predicted the prognosis of NSCLC [25] . Jiang et al. [26] reported that HE4 serves as a tumor marker for NSCLC, and its low expression can predict a poor prognosis of NSCLC patients. Ke et al. revealed that the over-expression of CTHRC1 was related to tumor aggressiveness and prognosis of human NSCLC [27] . It was demonstrated by Ji et al. that low expression of PTRN and over-expression of Ki67 were correlated with lymph node metastasis and malignant invasion of NSCLC [23] .
FOXD3 is a member of the winged-helix/fork-head transcription factor family, which is characterized by a conserved domain containing 100 residues and that is required for the activity of DNA-binding [18] . It is mainly expressed in the multi-potent cells, including embryonic stem cells and tumor cells. Reports have revealed that FOXD3 plays important roles in the maintenance and self-renewal of embryonic stem cells, and is strongly related to the early development of embryos [23] . Studies on the effects of FOXD3 on tumor stem cells have also been reported. Steiner et al. suggested that FOXD3 was essential for the development of xenopus dorsal mesoderm [28] . It was reported by Teng et al. that FOXD3 was required in maintaining the progenitors of the neural crest [29] . All these reports provide theories relevant to studying the relationship between FOXD3 and NSCLC.
In addition, Ectopic expression of FOXD3 has been reported in various diseases. Wang et al. reported that FOXD3 was downregulated in lung cancer and could suppress the development of this disease [11] . Low expression of FOXD3 in breast cancer was reported by Zhao et al. [21] . In the present study, we first detected the expression of FOXD3 in NSCLC patients, showing that the expression level of FOXD3 was significantly lower in NSCLC patients than in controls at mRNA and protein levels, which was in accord with previous studies. It can be concluded that FOXD3 might be a tumor suppressor in NSCLC.
Then, we assessed the correlation of FOXD3 with the tumorigenesis of NSCLC by analyzing the relationship of FOXD3 expression and clinical features of NSCLC patients. FOXD3 was proved to have close relationships with differentiation, TNM stage, and lymph node metastasis. Subsequently, in order to explore the diagnostic value of FOXD3 in patients with NSCLC, an ROC curve was built. As a result, a high AUC, as well as high sensitivity and specificity, were obtained, showing that FOXD3 is an independent diagnostic marker in NSCLC.
In previous studies, the precise mechanism and function of FOXD3 in the tumorigenesis and progression of diseases were revealed and it was reported that it cannot be regulated by some genes. For instance, Basile et al. showed that FOXD3 affects mutant B-RAF melanoma cells via regulating PLX4032/4720 [30] . Guo et al. found that FOXD3 interacted with Oct-4 to regulate the expression of endodermal specific promoter [31] . Liu et al. demonstrated that FOXD3 regulates the expression of microRNA-137 tumor growth in hepatocellular cancer [32] . However, its mechanisms in NSCLC remains unclear. Our group plans to explore this topic further in future research 
